XBiotech extends clinical manufacturing agreement with Janssen through December 2023

XBiotech Inc.

XBiotech entered a Manufacturing Agreement with Janssen R&D to produce clinical product including Bermekimab.
Agreement extends manufacturing support through December 2023; revenue extends cash runway for own pipeline.
Bermekimab, a True Human monoclonal antibody, was sold to Janssen in December 2019 with transitional manufacturing.
CEO John Simard stated contract manufacturing is not core business but fits well and provides runway for up-and-coming therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.